Neuren Pharmaceuticals (ASX:NEU) Ending Cash Position: A$4.23 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:NEU Neuren Pharmaceuticals Ltd ASX:NEU
48 GF Score
Price A$18.61
GF Value A$7.34
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Neuren Pharmaceuticals Ending Cash Position?

Neuren Pharmaceuticals ASX:NEU +0.11% 48 Ending Cash Position is A$4.23 Mil as of Dec. 2025. GuruFocus rates ASX:NEU with a GF Score™ of 48/100 and a GF Value™ of A$7.34 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Neuren Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2025 was A$4.23 Mil.

Neuren Pharmaceuticals's quarterly Ending Cash Position increased from Dec. 2024 (A$3.15 Mil) to Jun. 2025 (A$5.91 Mil) but then declined from Jun. 2025 (A$5.91 Mil) to Dec. 2025 (A$4.23 Mil).

Neuren Pharmaceuticals's annual Ending Cash Position declined from Dec. 2023 (A$17.09 Mil) to Dec. 2024 (A$3.15 Mil) but then increased from Dec. 2024 (A$3.15 Mil) to Dec. 2025 (A$4.23 Mil).

Neuren Pharmaceuticals Ending Cash Position Related Terms

Neuren Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Neuren Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuren Pharmaceuticals Ending Cash Position Chart

Neuren Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.78 40.18 17.09 3.15 4.23

Neuren Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.09 2.57 3.15 5.91 4.23
ASX:NEU
48GF Score
Neuren Pharmaceuticals Ltd ASX:NEU
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuren Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Neuren Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3.153+1.074
=4.23

Neuren Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5.906+-1.679
=4.23

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$4.23 Mil mean?
Neuren Pharmaceuticals (ASX:NEU) has a Ending Cash Position of A$4.23 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Neuren Pharmaceuticals and its competitors.
Is Neuren Pharmaceuticals' Ending Cash Position too high?
Neuren Pharmaceuticals' current Ending Cash Position is A$4.23 Mil. Overall, Neuren Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' Ending Cash Position compare to VRTX and REGN?
Neuren Pharmaceuticals' Ending Cash Position of A$4.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Neuren Pharmaceuticals and its competitors. Neuren Pharmaceuticals's current Ending Cash Position is A$4.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (ASX:NEU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$7.34, compared to a current price of A$18.61 — trading 153.5% above its estimated fair value. The current Ending Cash Position is A$4.23 Mil. Neuren Pharmaceuticals' overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Neuren Pharmaceuticals (ASX:NEU), the current Ending Cash Position is A$4.23 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuren Pharmaceuticals (ASX:NEU) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of A$18.61 is trading 153.5% above its estimated GF Value™ of A$7.34. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ASX:NEU:

  • Ending Cash Position: A$4.23 Mil
  • GF Value™: A$7.34 vs. price of A$18.61 (153.5% above fair value)
  • GF Score™: 48/100 with 2 warning signs

No single metric tells the full story. See the ASX:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuren Pharmaceuticals Business Description

Other Exchanges NURPF:USANK9:Germany
Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
48GF Score

Get the complete analysis for ASX:NEU

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$18.61
Price
A$7.34
GF Value